CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of June 30, 2022 and for the six months ended June 30, 2022 and 2021 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) | --- | --- | --- | --- | |---------------------------------------------------------------|-------|-------------------------------------|---------------------------| | (in thousands of EUR, except per share amounts) | Note | Six months \n2021 (unaudited) | e ...

Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of March 31, 2022 and for the three months ended March 31, 2022 and 2021 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) | --- | --- | --- | --- | |---------------------------------------------------------------|-------|---------------------------------------|----------------------------| | (in thousands of EUR, except per share amounts) | Note | Three months ...

CureVac NV (NASDAQ:CVAC) Q4 2021 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Sarah Fakih - VP Corporate Communications & IR Franz-Werner Haas - CEO Klaus Edvardsen - Chief Development Officer Pierre Kemula - CFO Conference Call Participants Douglas Buchanan - JMP Securities Eun Yang - Jefferies Zhiqiang Shu - Berenberg Operator Greetings. Welcome to the CureVac Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call. [Operator Instructions]. Please ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Exhibit 99.1 CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update · Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone o Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation o Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vac ...

CureVac N.V. (NASDAQ:CVAC) Q3 2021 Earnings Conference Call November 19, 2021 8:00 AM ET Company Participants Sarah Fakih – Vice President-Corporate Communications and Investor Relations Franz-Werner Haas – Chief Executive Officer Klaus Edvardsen – Chief Development Officer Pierre Kemula – Chief Financial Officer Mariola Fotin-Mleczek – Chief Technology Officer Conference Call Participants Manos Mastorakis – Deutsche Bank Evan Wang – Guggenheim Securities Jonathan Miller – Evercore ISI Zhiqiang Shu – Berenb ...

Exhibit 99.1 CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60 · Unique pivotal study conducted in 10 countries in fast changing variant environment; 15 COVID-19 variant strains present for ef icacy analysis; original strain almost completely absent · Statistical success criteria for primary endpoint met on basis of 228 adjudicated cases · Vaccine ef icacy of 48% against COVID-19 of any severity across all age gr ...

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ ☒ FORM 20-F (Mark One) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR SHELL COMPANY REPORT PURSUANT TO SECTIO ...